Isthmus Partners LLC cut its position in shares of Celgene Corporation (NASDAQ:CELG) by 4.1% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 52,089 shares of the biopharmaceutical company’s stock after selling 2,235 shares during the quarter. Celgene Corporation comprises 2.0% of Isthmus Partners LLC’s investment portfolio, making the stock its 14th biggest holding. Isthmus Partners LLC’s holdings in Celgene Corporation were worth $6,765,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CELG. BlackRock Inc. boosted its position in shares of Celgene Corporation by 5.7% during the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after purchasing an additional 3,084,227 shares in the last quarter. Oaktop Capital Management II L.P. bought a new stake in shares of Celgene Corporation during the second quarter valued at approximately $271,605,000. Harbour Capital Advisors LLC boosted its position in shares of Celgene Corporation by 12,913.6% during the second quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock valued at $12,222,000 after purchasing an additional 1,575,074 shares in the last quarter. Investec Asset Management LTD bought a new stake in shares of Celgene Corporation during the first quarter valued at approximately $194,490,000. Finally, Clearbridge Investments LLC boosted its position in shares of Celgene Corporation by 24.1% during the first quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after purchasing an additional 892,392 shares in the last quarter. Institutional investors own 79.48% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/celgene-corporation-celg-stake-decreased-by-isthmus-partners-llc/1722979.html.

In other news, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders sold 20,227 shares of company stock valued at $2,843,956 in the last 90 days. Company insiders own 0.95% of the company’s stock.

Several research firms recently weighed in on CELG. Cann restated a “buy” rating and set a $166.00 price target on shares of Celgene Corporation in a research report on Wednesday. TheStreet lowered Celgene Corporation from a “b-” rating to a “c+” rating in a research report on Friday, November 17th. BMO Capital Markets lifted their price objective on Celgene Corporation from $148.00 to $155.00 and gave the company an “outperform” rating in a research note on Friday, November 17th. Canaccord Genuity set a $140.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, November 16th. Finally, Oppenheimer Holdings, Inc. set a $166.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, November 16th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $139.57.

Celgene Corporation (CELG) opened at $105.16 on Friday. Celgene Corporation has a one year low of $94.55 and a one year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $82,794.26, a price-to-earnings ratio of 16.43, a PEG ratio of 0.81 and a beta of 1.79.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the previous year, the business earned $1.58 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. research analysts expect that Celgene Corporation will post 6.67 EPS for the current fiscal year.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.